This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Collaborations, Conferences, And Recognitions - Analyst Notes On Illumina, Alexion, Medtronic, Sirona, And NPS Pharmaceuticals

NEW YORK, March 5, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts Review released its analysts' notes regarding Illumina, Inc. (NASDAQ:ILMN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Medtronic, Inc. (NYSE: MDT), Sirona Dental Systems, Inc. (NASDAQ: SIRO), and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Illumina, Inc. Analyst Notes

On February 24, 2014, Illumina, Inc. (Illumina) reported that its Illumina Genome Network (IGN) the Sweden-based Science for Life Laboratory (SciLifeLab) has joined IGN to provide researchers with wider access to Illumina's whole genome sequencing technology. SciLifeLab is the first IGN partner in Europe and will initiate a national large-scale population sequencing program seeking to identify genetic causes of human diseases. According to Illumina, IGN links researchers needing large-scale, whole human genome sequencing with world class institutions that provide this service, and delivers unmatched access to the highest quality of whole genome sequencing data. Commenting on the news, Joakim Lundeberg, Professor in Gene Technology at KTH Royal Institute of Technology and Director of the National Genomics Infrastructure at Science for Life Laboratory, said, "We now have the opportunity to offer an even larger capacity of high throughput sequencing to researchers from all over Sweden. In the research program we are about to launch, we aim to sequence more than 1,000 human genomes using the Illumina systems." The full analyst notes on Illumina, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03052014/ILMN/report.pdf

--

Alexion Pharmaceuticals, Inc. Analyst Notes

On March 3, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced that it has received acknowledgement from the National Institute for Health and Clinical Excellence (NICE) for eculizumab (Soliris®) as a very effective treatment option for patients with aHUS, and that the use of eculizumab would be of significant value to patients with this life-threatening disorder who have no other treatment options. Alexion also stated that the positive NICE assessment aligns with the two prior positive recommendations from Government - AGNSS and NHS England. In addition, NICE confirmed that the broad interim NHS England commissioning policy for eculizumab treatment of existing and new patients with aHUS will continue. The full analyst notes on Alexion Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03052014/ALXN/report.pdf

--

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,051.73 -48.45 -0.28%
S&P 500 1,973.63 -4.59 -0.23%
NASDAQ 4,424.7040 -7.4420 -0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs